Eradication of hepatitis C infection: The importance of targeting people who inject drugs

Authors

  • Margaret Hellard,

    Corresponding author
    1. Centre for Population Health, Burnet Institute, Melbourne, Victoria, Australia
    2. Infectious Diseases Unit, The Alfred Hospital, Melbourne, Victoria, Australia
    3. Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia
    • Address reprint requests to: Prof. Margaret Hellard, Centre for Population Health, Burnet Institute, 85 Commercial Road, Melbourne VIC 3004, Australia. E-mail: hellard@burnet.edu.au; fax: +61 3 9282 2138.

    Search for more papers by this author
  • Joseph S. Doyle,

    1. Centre for Population Health, Burnet Institute, Melbourne, Victoria, Australia
    2. Infectious Diseases Unit, The Alfred Hospital, Melbourne, Victoria, Australia
    3. Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia
    4. Victorian Infectious Diseases Service, Royal Melbourne, Hospital, Parkville, Victoria, Australia
    Search for more papers by this author
  • Rachel Sacks-Davis,

    1. Centre for Population Health, Burnet Institute, Melbourne, Victoria, Australia
    2. Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Victoria, Australia
    Search for more papers by this author
  • Alexander J. Thompson,

    1. Victorian Infectious Disease Service, Royal Melbourne Hospital, Parkville, Victoria, Australia
    2. Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia
    Search for more papers by this author
  • Emma McBryde

    1. Centre for Population Health, Burnet Institute, Melbourne, Victoria, Australia
    2. Victorian Infectious Diseases Service, Royal Melbourne, Hospital, Parkville, Victoria, Australia
    Search for more papers by this author

  • Potential conflict of interest: M.H., J.D., R.S.D., E.M.: no conflicts of interest to declare. A.T.: Research/grant support, Merck, Roche, Gilead; Consulting/ advisory capacity, Merck, Roche, Janssen-Cilag (Johnson and Johnson), Gilead, Novartis; Speaker's fee, Merck, Roche, Bristol-Myers Squibb, Bayer, Janssen, Gilead. Coinventor of a patent related to the IL28B-HCV discovery.

  • M.H., J.D., R.S.D., A.T., and E.M. are supported by the National Health and Medical Research Council. J.D. and R.S.D. are supported by the NHMRC-funded Centre for Research Excellence into Injecting Drug Use. The authors acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program (Department of Health, Victoria, Australia) to the Burnet Institute.

Ancillary